Results 1 to 10 of about 14,513 (154)
Targeting lipid metabolism overcomes BTK inhibitor resistance in diffuse large B-cell lymphoma
Medicine in Novel Technology and DevicesExploring novel therapeutic targets of Diffuse large B cell lymphoma (DLBCL) to overcome its resistance to Bruton's Tyrosine Kinase (BTK) inhibitors is a key topic.
Zhuojun Liu +5 more
doaj +3 more sources
Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib.
PLoS ONE, 2023 Bruton's tyrosine kinase (BTK) is the target of the therapeutic agent, Ibrutinib, that treats chronic lymphocyte leukemia (CLL), mantle cell lymphoma (MCL) and other B cell malignancies. Ibrutinib is a first in class, covalent BTK inhibitor that limits B-
David Y Lin, Amy H Andreotti
doaj +2 more sources
Клиническая онкогематология, 2023 New Bruton’s tyrosine kinase (BTK) inhibitors caused drastic modifications in the therapy of chronic lymphocytic leukemia (CLL). Ibrutinib, the first in its class BTK inhibitor, showed high efficacy in many clinical studies.
A. A. Petrenko +4 more
doaj +1 more source
Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors
Journal of Enzyme Inhibition and Medicinal Chemistry, 2022 Bruton tyrosine kinase (BTK) is linked to multiple signalling pathways that regulate cellular survival, activation, and proliferation. A covalent BTK inhibitor has shown favourable outcomes for treating B cell malignant leukaemia.
Tony Eight Lin +10 more
doaj +1 more source
Biomarker Research, 2022 The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The first-in-class BTK inhibitor ibrutinib has shown remarkable therapeutic effects and manageable toxicities in ...
Jing Zhang +3 more
doaj +1 more source
Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus
Frontiers in Medicine, 2021 Bruton Tyrosine Kinase (BTK) has a key role in multiple pathways involved in inflammation and autoimmunity. Therefore, BTK has become a new therapeutic target for a group of hematologic and autoimmune disorders.
Aikaterini Patsatsi, Dedee F. Murrell
doaj +1 more source
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
eLife, 2020 Bruton’s tyrosine kinase (BTK) is targeted in the treatment of B-cell disorders including leukemias and lymphomas. Currently approved BTK inhibitors, including Ibrutinib, a first-in-class covalent inhibitor of BTK, bind directly to the kinase active site.
Raji E Joseph +5 more
doaj +1 more source
Zanubrutinib in lymphoproliferative disorders: a comprehensive review
Therapeutic Advances in Hematology, 2022 The availability of Bruton tyrosine kinase (BTK) inhibitors has brought about a paradigm shift in the treatment of patients with B-cell lymphomas and chronic lymphocytic leukemia.
Javier Muñoz +3 more
doaj +1 more source
The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
Clinical Hematology International, 2022 The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström’s Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease.
Obada Ababneh +4 more
doaj +1 more source
Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations
Therapeutic Advances in Hematology, 2022 Bruton’s tyrosine kinase (BTK) inhibitors have dramatically changed the treatment of newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL).
Alexandra R. Lovell +2 more
doaj +1 more source